TrialCancer research and treatment2026

A Multicenter Phase II Study of Modified FOLFIRINOX for First-Line Treatment for Advanced Urachal Cancer (ULTIMA; KCSG GU20-03).

Inkeun Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.